obesity overweight weight loss weigh
Biotech

Roche, Zealand see phase 2 amylin weight loss peak at mid-dose

Zealand shared primary endpoint data on petrelintide, revealing that the middle dose delivered the highest weight loss—9.8%—at Week 28.
Nick Paul Taylor Sep 30, 2026 4:57am
New approach methodologies in safety and toxicology testing Why proving repeatability is the next hurdle for widespread adop

NAMs: Why proving repeatability is the next hurdle for widespread adoption

Brought to you by Agilent Technologies
Amgen

Amgen reveals 6-point drop in lupus severity behind ph. 2 win

Sep 30, 2026 4:26am
Lilly

Lilly sets up next-gen obesity war with phase 3 retatrutide data

Sep 30, 2026 3:06am
Eli Lilly Lilly

Lilly raises diabetes weight-loss bar with amylin-Zepbound combo

Sep 30, 2026 1:52pm
Judge gavel with bright glowing futuristic orange neon lights

Beam sues rival startup, claims former scientist stole secrets

Sep 30, 2026 10:42am
More News

Merck’s anti-TL1A secures a ph. 2 hidradenitis suppurativa win

Sep 30, 2026 10:20am

Fierce Biotech Fundraising Tracker '26: AnaCardio, Breye & more

Sep 30, 2026 9:30am

GSK continues stockpiling Wave drugs with liver-focused program

Sep 30, 2026 9:19am

Highlight Therapeutics illuminates positive data in skin cancer

Sep 30, 2026 9:00am